Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready
Accutar Biotechnology Inc. has 5 pending office actions in the Biotechnology & Pharmaceuticals sector. The portfolio is highly distributed, with 5 distinct examiners each handling a portion of the workload. This distribution between pending actions and examiners indicates that no individual examiner has a dominant influence over the current prosecution pipeline. Such a distribution can be advantageous as it mitigates the risk of a single difficult examiner stalling the entire portfolio.
The 5 pending office actions are spread across 3 distinct art units, showing some level of technological variety within the company's primary field. HUTTER, GILLIAN A is identified as the busiest examiner, currently overseeing 1 pending office action. Practitioners should prepare for varied feedback given the involvement of 3 distinct art units, which may have different standards for disclosure or utility. Managing 5 distinct examiners requires a flexible strategy that accounts for individual procedural preferences.
Despite the variety, the concentration in the Biotechnology & Pharmaceuticals area remains the defining characteristic of these 5 pending office actions. The involvement of multiple art units suggests that the company's research spans multiple sub-specialties, requiring a nuanced approach to each filing. Because HUTTER, GILLIAN A only handles 1 pending office action, the applicant must maintain active communication channels with the other distinct examiners to ensure consistent progress across the current pending matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §103 only | 1 (20%) |
| §112 only | 1 (20%) |
| Double-patenting only | 1 (20%) |
| No statute on record | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUTTER, GILLIAN A | 1 | 54.5% | +46.2% |
| KOSACK, JOSEPH R | 1 | 74.8% | -6.2% |
| SANDERSON, LEE E | 1 | 45.4% | +44.6% |
| SEITZ, ANTHONY JOSEPH | 1 | 68.3% | +27.0% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18263656 | SUBSTITUTED PYRROLOPYRIMIDINE AND PYRAZOLOPYRIMIDINE AS BRUTON'S TYROSINE KINASE (BTK) DEGRADERS | WILLIS, DOUGLAS M | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18476063 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | SEITZ, ANTHONY JOSEPH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18707106 | NOVEL SPIROCYCLIC COMPOUNDS AS KLHDC2 LIGANDS | HUTTER, GILLIAN A | — |
| 18404740 | CHROMAN DERIVATIVES HAVING ESTROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | SANDERSON, LEE E | — |
| 18476063 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | SEITZ, ANTHONY JOSEPH | — |
| 18263656 | SUBSTITUTED PYRROLOPYRIMIDINE AND PYRAZOLOPYRIMIDINE AS BRUTON'S TYROSINE KINASE (BTK) DEGRADERS | WILLIS, DOUGLAS M | — |
| Art Unit | Apps |
|---|---|
| 3991 | 2 |
| 1629 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18707106 | NOVEL SPIROCYCLIC COMPOUNDS AS KLHDC2 LIGANDS | HUTTER, GILLIAN A | — | §103 | Non-Final OA | — | Pending | May 02, 2024 |
| 18591704 | CHROMAN DERIVATIVES HAVING ESTROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | KOSACK, JOSEPH R | 3991 | Other | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18404740 | CHROMAN DERIVATIVES HAVING ESTROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | SANDERSON, LEE E | 3991 | DP | Non-Final OA | — | Pending | Jan 04, 2024 |
| 18476063 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | SEITZ, ANTHONY JOSEPH | 1629 | §101§102 | Final Rejection | — | Pending | Sep 27, 2023 |
| 18263656 | SUBSTITUTED PYRROLOPYRIMIDINE AND PYRAZOLOPYRIMIDINE AS BRUTON'S TYROSINE KINASE (BTK) DEGRADERS | WILLIS, DOUGLAS M | 1624 | §112Other | Non-Final OA | — | Pending | Jul 31, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial